Progress on Aß-Targeted therapeutic strategies for Alzheimer's disease

Progress in Biochemistry and Biophysics

Volumn 39, Issue 8, 2012, Pages 734-740

  Hua, Qian ^a   Ding, Hai Min ^a   Liang, Mi ^a  

^a BEIJING UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

amyloid peptides; Alzheimer's disease; Immunotherapy; Presymptomatical treatment

Indexed keywords

EID: 84870908520     PISSN: 10003282     EISSN: None     Source Type: Journal    
DOI: 10.3724/SP.J.1206.2012.00215     Document Type: Review

References (53)

1. Hardy J A, G.A. Higgins Alzheimer's discascascade hypothesis. Science, 1992,256(5054): 184-185
2. Ling Y, Morgan K, Kalsheker N. Amyloid precursor protein (APP) and the biology of proteolytic processing: relevance to Alzheimer's disease. Int J Biochem Cell Biol, 2003,35(11): 1505-1535 (Pubitemid 36724946)
3. Imbimbo B P. Therapeutic potential of secretase inhibitors and modulators. CurrTop Med Chem, 2008,8(1): 54-61 (Pubitemid 351791047)
4. Wong G T, Manfra D, Poulet F M, et al. Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation. J Biol Chem, 2004, 279(13): 12876-12882 (Pubitemid 38445862)
5. Siemers E, Skinner M, Dean R A, et al. Safety, tolerability, and changes in amyloid beta concentrations after administration of a gamma-secretase inhibitor in volunteers. Clin Neuropharmacol, 2005,28(3): 126-132 (Pubitemid 40923411)
6. Imbimbo B P, Giardina G A. gamma-secretase inhibitors and modulators for the treatment of Alzheimer's disease: disappointments and hopes. Curr Top Med Chem, 2011, 11(12): 1555-1570
7. Wilcock G K, Black S E, Hendrix S B, et al. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol, 2008,7(6): 483-493
8. Luo Y, Bolon B, Kahn S, et al. Mice deficient in BACEl, the Alzheimer's beta-secretase, have normal phenotype and abolished ß-amyloid generation. Nat Neurosci, 2001,4(3): 231-232 (Pubitemid 32194866)
9. Hussain I, Hawkins J, D Harrison D, et al. Oral administration of a potent and selective non-peptidic BACE-1 inhibitor decreases beta-cleavage of amyloid precursor protein and amyloid-beta production in vivo. J Neurochem, 2007,100(3): 802-809 (Pubitemid 46095629)
10. Colciaghi F, Borroni B, Zimmermann M, et al. editors. Amyloid precursor protein metabolism is regulated toward alpha-secretase pathway by Ginkgo biloba extracts. Neurobiol Dis, 2004, 16(2): 454-460 (Pubitemid 38757325)
11. Necula M, Kayed R, Milton S, et al. Small molecule inhibitors of aggregation indicate that amyloid beta oligomerization and fibrillization pathways are independent and distinct. J Biol Chem, 2007,282(14): 10311-10324 (Pubitemid 47093410)
12. Aisen P S, Saumier D, Briand R, et al. A Phase II study targeting amyloid-beta with 3APS in mild-to-moderate Alzheimer disease. Neurology, 2006,67(10): 1757-1763 (Pubitemid 44900749)
13. Wright T M. Tramiprosate. Drugs Today (Bare), 2006, 42(5): 291-298 (Pubitemid 43980714)
14. Cuajungco M P, Frederickson C J, Bush A I. Amyloid-beta metal interaction and metal chelation. Subcell Biochem, 2005, 38:235-254
15. Ritchie C W, Bush A I, Mackinnon A, et al. Metal-protein attenuation with iodochlorhydroxyquin (clioquinol) targeting Abeta amyloid deposition and toxicity in Alzheimer disease: a pilot phase 2 clinical trial. Arch Neurol, 2003,60(12): 1685-1691 (Pubitemid 37521621)
16. De Strooper B, Saftig P, Craessaerts K, et al. Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein. Nature, 1998, 391(6665): 387-390 (Pubitemid 28093512)
17. Miller B C, Eckman E A, Sambamurti K, et al. Amyloid-beta peptide levels in brain are inversely correlated with insulysin activity levels in vivo. Proc Natl Acad Sei USA, 2003, 100(10): 6221-6226 (Pubitemid 36576957)
18. Yasojima K, McGeer E G, McGeer P L. Relationship between beta amyloid peptide generating molecules and neprilysin in Alzheimer disease and normal brain. Brain Res, 2001,919(1): 115- 121
19. Tokita K, Inoue T, Yamazaki S, et al. FK962, a novel enhancer of somatostatin release, exerts cognitive-enhancing actions in rats. Eur J Pharmacol, 2005,527(1-3): 111-120 (Pubitemid 41745158)
20. Schenk D, Barbour R, Dunn W, et al. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature, 1999,400(6740): 173-177 (Pubitemid 29327547)
21. Oddo S, Billings L, Kesslak J P, et al. Abeta immunotherapy leads to clearance of early, but not late, hyperphosphorylated tau aggregates via the proteasome. Neuron, 2004,43(3): 321 -332
22. Orgogozo J M, Gilman S, Dartigues J F, el al. Subacute meningoencephalitis in a subset of patients with AD after Abeta42 immunization. Neurology, 2003,61(1): 46-54 (Pubitemid 36818745)
23. Ryan J M, Grundman M. Anti-amyloid-beta immunotherapy in Alzheimer's disease: ACC-001 clinical trials are ongoing. J Alzheimers Dis, 2009,17(2): 243
24. Blennow K, Zetterberg H, Rinne J O, et al. Effect of immunotherapy with bapineuzumab on cerebrospinal fluid biomarker levels in patients with mild to moderate Alzheimer disease. Arch Neurol, 2012,DOI:10.1001/archneurol.2012.90
25. Grundman M, Petersen R C, Ferris S H, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol, 2004,61(1): 59-66 (Pubitemid 38067415)
26. Rinne J O, Brooks D J, Rossor M N, et al. 11C-PiB PET assessment of change in fibrillar amyloid-beta load in patients with Alzheimer's disease treated with bapineuzumab: a phase 2, double-blind, placebo-controlled, ascending-dose study. Lancet Neurol, 2010, 9(4): 363-372
27. Wilcock D M, Colton C A. Immunotherapy, vascular pathology, and microhemorrhages in transgenic mice. CNS Neurol Disord Drug Targets, 2009,8(1): 50-64
28. Holmes C, Boche D, Wilkinson D, et al. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial. Lancet. 2008, 372(9634): 216-223 (Pubitemid 351978111)
29. Wilcock D M, Gharkholonarehe N, Van Nostrand W E, et al. Amyloid reduction by amyloid-beta vaccination also reduces mouse tau pathology and protects from neuron loss in two mouse models of Alzheimer's disease. J Neurosci, 2009,29(25): 7957-7965
30. Racke M M, Boone L I, Hepburn D L, et al. Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci, 2005,25(3): 629-636
31. Yan P, Bero A W, Cirrito J R, et al. Characterizing the appearance and growth of amyloid plaques in APP/PS1 mice. J Neurosci, 2009, 29(34): 10706-10714
32. Castellani R J, Lee H G, Siedlak S L, et al. Reexamining Alzheimer's disease: evidence for a protective role for amyloidbeta protein precursor and amyloid-beta. J Alzheimers Dis, 2009,18(2): 447-452
33. Puzzo D, Privitera L, Leznik E, el al. Picomolar amyloid-ß positively modulates synaptic plasticity and memory in hippocampus. J Neurosci, 2008,28(53): 14537-14545
34. Morley J E, Farr S A, Banks W A, et al. A physiological role for amyloid-ß protein: enhancement of learning and memory. J Alzheimers Dis, 2010,19(2): 441-449
35. Perrin R J, Fagan A M, Holtzman D M. Multimodal techniques for diagnosis and prognosis of Alzheimer's disease. Nature, 2009, 461(7266): 916-922
36. Struble R G, Ala T, Patrylo P R, et al. Is brain amyloid production a cause or a result of dementia of the Alzheimer's type?. J Alzheimers Dis, 2010,22(2): 393-399
37. Klunk W E, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol, 2004,55:306-319
38. Vlassenko A G, Mintun M A, Xiong C, et al. Amyloid-beta plaque growth in cognitively normal adults: longitudinal [11C] Pittsburgh compound B data. Ann Neurol, 2011, 70(5): 857-861
39. Holtzman D M. Alzheimer's disease: Moving towards a vaccine. Nature News, 2008,454 (24): 418-420
40. Zhou J W. Recent progress in neurodegenerative disorder research in China. Sei China Life Sci, 2010,53: 348-355
41. Cong L, Jia J. Promoter polymorphisms which regulate ADAM9 transcription are protective against sporadic Alzheimer's disease. Neurobiol Aging, 2011, 32(1): 54-62
42. Tong Z Q, Han C S, Luo W H, et al. Accumulated hippocampal formaldehyde induces age-dependent memory decline. Age, 2012, DOI: 10.1007/s11357-012-9388-8
43. He R Q, Lu J, Miao J Y. Formaldehyde stress. Sci China Life Sci, 2010,53(12): 1399-1404
44. Tong Z Q, Zhang J L, Luo W H, et al. Urine formaldehyde level is inversely correlated to mini mental state examination scores in senile dementia. Neurobiology of Aging, 2011,32(1): 31-41
45. Liu Y Y, Qiang M, Wei Y, et al. A novel molecular mechanism for nitrated a-synuclein-induced cell death. J Mol Cell Biol, 2011, 3(4): 239-249
46. Sajjad Haider Naqvi, Wang W S, Miao J Y, et al. Prag Biochem Biophys, 2010,37(11): 1195-1203
47. Zhang X H, Poo M M. Progress in neural plasticity. Sci China Life Sci, 2010,53(3): 322-329
48. Luo Z G. Synapse formation and remodeling. Axon guidance and neuronal migration research in China. Sci China Life Sci, 2010, 53(3): 315-321
49. Zhang M, Zhao Z M, He L, et al. A meta-analysis of oxidative stress markers in schizophrenia. Sci China Life Sci, 2010,53(1): 112-124
50. Sun P, Zhang Q, Han J Y, et al. TLR4 signaling induced TLR2 expression in the process of mimic cerebral ischemia/reperfusion in vitro. Sci China Life Sci, 2010,53(2): 223-228
51. Wang Y Z, Xu T L. Ion channels in neuronal survival. Sci China Life Sci, 2010,53: 342-347
52. Luo Y F, Zhang J, Liu N Q, et al. Copper ions influence the toxicity of ß-amyloid (1-42) in a concentration-dependent manner in a Caenorhabditis elegans model of Alzheimer's disease. Sci China Life Sci, 2011, 54(6): 527-534
53. Liu L L, Sheng B Y, Gong K, et al. Prog Biochem Biophys, 2010, 37(2): 154-160